SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for PerkinElmer, Inc. for the period ended October 1, 2006. The company operates in two primary segments: Life and Analytical Sciences (drug discovery, genetic screening, environmental analysis) and Optoelectronics (digital imaging, sensors, specialty lighting). The filing covers the three and nine months ended October 1, 2006, compared to the same periods in 2005.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 1, 2006 | 9 Months Ended Oct 1, 2006 |
|---|---|---|
| Sales | $386,917 | $1,119,372 |
| Operating Income | $36,515 | $101,200 |
| Net Income | $29,753 | $77,855 |
| Diluted EPS | $0.24 | $0.61 |
| Cash and Equivalents | $207,074 | $207,074 (Balance Sheet) |
| Long-term Debt | $201,133 | $201,133 (Balance Sheet) |
| Operating Cash Flow | N/A | $43,215 |
Margins (9 Months): Gross margin decreased to 40.1% (from 41.4% in 2005). Operating margin was approximately 9.0%.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 7% in the quarter and 3% for the nine-month period. Growth was driven by acquisitions ($7.1M impact in Q3) and favorable foreign exchange rates in the quarter, though FX was unfavorable for the nine-month period.
- Profitability: Operating income decreased 11% in the quarter ($36.5M vs $41.2M) due to lower gross margins and increased stock-based compensation. However, for the nine-month period, operating income increased 11% ($101.2M vs $91.5M), primarily due to a significant reduction in restructuring charges ($1.1M in 2006 vs $11.0M in 2005).
- Discontinued Operations: The company recognized a net gain of $1.6M on dispositions of discontinued operations for the nine months ended Oct 1, 2006, compared to a loss of $4.5M in the prior year. This includes the sale of the Semiconductor business.
- Stock-Based Compensation: Adoption of SFAS No. 123(R) resulted in incremental stock-based compensation expense of $6.9M for the nine months ended Oct 1, 2006.
Guidance, Outlook, and Risks
- Acquisitions: The company completed several acquisitions in 2006, including Agilix, Spectral Genomics, C&A, J.N. Macri/NTD, and Avalon Instruments, totaling approximately $93.5M in net cash used. These are expected to bolster the Life and Analytical Sciences segment.
- Stock Repurchases: The company completed a $190.1M repurchase of 8.9M shares in the first nine months of 2006, fulfilling a 10M share program. A new program authorizing up to 10M additional shares was announced on November 6, 2006.
- Restructuring: Ongoing restructuring plans (Q2 2006, Q4 2005, Q2 2005) remain active with remaining liabilities of approximately $2.0M expected to be paid by year-end 2006.
- Legal Contingencies: Significant patent litigation is ongoing with Enzo Biochem and Amersham Biosciences. The company believes it has meritorious defenses but cannot estimate potential losses. Environmental liabilities are accrued at $3.7M.
- Liquidity: The company maintains a $350M senior unsecured revolving credit facility with $200.9M outstanding as of Oct 1, 2006. It is in compliance with all financial covenants.
Investor Verification Checklist
- Margin Compression: Verify the sustainability of gross margins given the cited unfavorable commodity costs and product mix shifts compared to the prior year.
- Acquisition Integration: Monitor the financial contribution of recent acquisitions (Agilix, Spectral, Macri/NTD, Avalon) to the Life and Analytical Sciences segment.
- Legal Exposure: Track the status of the Amersham and Enzo patent lawsuits, as adverse rulings could impact product sales or result in significant damages.
- Debt Structure: Confirm the impact of the new $350M credit facility and the repayment of senior subordinated notes on future interest expense.
- Discontinued Operations: Ensure clarity on the final settlement of working capital adjustments related to the divestiture of the Fluid Sciences segment.